About Biomeme
Biomeme is a Healthcare company based in Philadelphia (United States) founded in 2013. Smartphone-based DNA detection platform is developed for diagnostics. Biomeme has raised $6.2 million across 7 funding rounds from investors including European Union, EIC Fund and Ben Franklin Technology Partners. Biomeme has completed 1 acquisition, including Predigen. Biomeme offers products and services including Franklin ISP, Franklin Your Platform, and Tests Pipeline. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Genomics. Its competitors include DermTech, Inflammatix and GenMark Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
Biomeme was founded in 2013 in Philadelphia, United States, within the biotechnology sector. A smartphone-based platform for DNA diagnostics is provided, enabling real-time qPCR through a docking station, sample preparation with targeted test kits, and result analysis via a mobile app. Operations focus on pathogen identification by DNA or RNA signatures, with initial applications directed toward sexually transmitted disease panels.
- Total Equity Funding$6.2M (USD)
in 7 rounds
- Latest Funding Round$4.51M (USD), Series A
May 2017
- InvestorsEuropean Union
& 3 more
- Investments & Acquisitions
Products & Services of Biomeme
Biomeme offers a comprehensive portfolio of products and services, including Franklin ISP, Franklin Your Platform, and Tests Pipeline.
Portable system for efficient molecular testing in remote areas.
Streamlines collaborative research with advanced diagnostics tools.
Facilitates rapid analysis for infectious disease detection.
Apps and channels of Biomeme
its YouTube channel Biomeme has 10 subscribers and 11 videos.
Videos from Biomeme
The most watched videos on Biomeme's YouTube channel, Biomeme (10 subscribers). Click a video to play it here.
More on Biomeme.
Funding Insights of Biomeme
Biomeme has successfully raised a total of $6.2M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $4.51 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.2M
- Total Rounds 7
- Last Round Series A — $4.51M
- Investors Count 4
All 7 funding rounds of Biomeme with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2017 | $4.51M | Series A | – | – | – |
| Sep 2016 | $56,109 | Grant | – | – | |
| Jun 2016 | $55,934 | Grant | – | – | |
| Feb 2014 | $400,000 | Seed | – | Ben Franklin Technology Partners | – |
| Jan 2014 | $992,799 | Seed | – | – | – |
| Dec 2013 | $300,000 | Seed | – | – | – |
| Jul 2013 | Seed | – | – |
4 investors in total: 4 institutional.
Investors in Biomeme
Biomeme has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, EIC Fund and Ben Franklin Technology Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Technology ecosystem growth is supported in Southeastern Pennsylvania. | sep.benfranklin.org | Philadelphia, United States | ||
Startup accelerator | dreamit.com | New York, United States | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Biomeme
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biomeme
8 people are tracked at Biomeme (8 in leadership).
| Name | Role | Group |
|---|---|---|
Katie Edwards | VP of Quality & Regulatory | Leadership |
Dave Kovscek | CFO | Leadership |
Joe Tumolo | VP of Sales | Leadership |
Karen Griffith Gryga | COO | Leadership |
Marc DeJohn | Co-Founder & EVP, Engineering | Leadership |
Max Perelman | Co-Founder, President & CEO | Leadership |
Jesse vanWestrienen | Co-Founder & EVP, Products | Leadership |
Anthony Washington | Associate Director of Project Management | Leadership |
Complete people profiles for Biomeme
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biomeme
Biomeme has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Predigen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene expression signatures are developed for disease diagnostics. | predigen.com | United States | 2014 | Aug 2021 | •••• |
Complete acquisition details for Biomeme
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biomeme
4 dated milestones of Biomeme across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Biomeme is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $4.5M.
- Acquisition Acquires Predigen.
Competitors of Biomeme
Biomeme has 3 listed competitors in our database, 3 of them funded. They include DermTech, Inflammatix and GenMark Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dermtech.com | 1996 | San Diego, United States | $24.37M | 259 | Adhesive patch biopsies for skin cancer detection are provided. | |
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. |
Detailed competitors of Biomeme
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biomeme
The website of Biomeme (biomeme.com) receives about 4.2K visits a month.
- Monthly visits4.2K
▼ 6% vs previous month
Websites whose visitors overlap most with Biomeme. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
waterra.com | waterra.com | 100% | #3,583,763 | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Biomeme (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biomeme
Complete news archive for Biomeme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biomeme
Biomeme was founded in 2013.
Biomeme is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Biomeme is a funded company, having raised a total of $6.2M across 7 funding rounds to date.
Biomeme was founded in 2013 in Philadelphia, United States, within the biotechnology sector. A smartphone-based platform for DNA diagnostics is provided, enabling real-time qPCR through a docking station, sample preparation with targeted test kits, and result analysis via a mobile app. Operations focus on pathogen identification by DNA or RNA signatures, with initial applications directed toward sexually transmitted disease panels.
Biomeme's top competitors include Inflammatix, DermTech and GenMark Diagnostics.
Biomeme offers Franklin ISP, Franklin Your Platform, and Tests Pipeline.
Biomeme has made 1 acquisition, including Predigen.
Biomeme has 4 investors. Key investors include European Union, EIC Fund, Ben Franklin Technology Partners, and Dreamit.